Project Grant R01CA301542
Award Date
4/2/25
Completion Date
3/31/30
Dollars Obligated
$523K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $485,558 over 5 years to The General Hospital Corporation (Massachusetts General Hospital) for a study on a novel glutathione-dependent metabolic pathway that drives metastatic outgrowth in pancreatic cancer. The research aims to molecularly characterize key factors involved in this pathway, with the potential to develop new diagnostic markers and therapeutic strategies for treating...
This $636,046 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Weill Medical College of Cornell University aims to define the role of different KRAS oncogene variants in pancreatic ductal adenocarcinoma (PDAC) progression and identify therapeutic vulnerabilities.
The research will (1) decipher how cell lineage impacts the neoplastic transformation and molecular evolution of epithelial cells in KRAS G12R and G12V mutant PDAC, (2) define the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $118,912 to the University of North Carolina at Chapel Hill to conduct research on the mechanistic relationship between oncogenic KRAS signaling, macropinocytosis, and autophagy in pancreatic ductal adenocarcinoma (PDAC). The research aims to: 1) Determine if upregulation of macropinocytosis confers resistance to dual autophagy and RAS-pathway inhibition for PDAC treatment;...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This $351,131 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Miami to disrupt the interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) in order to overcome resistance to chemoimmunotherapy in pancreatic cancer. The key objectives are to: 1) Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to Wayne State University to investigate the role of the RAN-RCC1 axis in driving the progression of pancreatic ductal adenocarcinoma (PDAC). The research aims to elucidate how overexpression of the RCC1 guanine exchange factor alters PDAC metabolic activity and mRNA processing to promote tumor progression and metastasis. The project period runs from Sep...
This $667,118 five-year Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the University of California, San Francisco (UCSF) to identify and target key lysosomal proteins that enable the growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), an incurable form of pancreatic cancer.
The primary objectives are to: 1) explore the role of the lysosomal hydrolase PLBD1 in supporting PDAC cell metabolism by removing...
The National Cancer Institute (NCI) awarded The Johns Hopkins University a $432,889 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct innovative research on reversing pancreatic cancer-induced cachexia. The five-year project aims to apply molecular and functional imaging capabilities, as well as theranostic nanoparticle technologies, to target the glutamine/glutamate axis and disrupt glutamine metabolism in preclinical pancreatic cancer models....
This $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of cellular metabolism in regulating precancerous stages of pancreatic cancer development.
The key products and services to be delivered through this 2-year grant include: 1) Mechanistic studies on how the metabolic enzyme ME1 contributes to acinar-to-ductal metaplasia (ADM) and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for research aimed at developing an innovative protein drug called PROAGIO to simultaneously target cancer-associated fibroblasts (CAFs) and abnormal tumor blood vessels in pancreatic ductal adenocarcinoma (PDAC). The $590,094 award to the University of Alabama at Birmingham (UAB) will support a Phase I clinical trial to evaluate the safety, pharmacokinetics, and preliminary...